The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance.SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment.See related commentary by Savona and Rathmell, p. 831.

[1]  Guihua Chen,et al.  Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation. , 2019, Cancer cell.

[2]  R. Collins,et al.  Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms , 2019, Nature Communications.

[3]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[4]  Fedor A. Kolpakov,et al.  GTRD: a database on gene transcription regulation—2019 update , 2018, Nucleic Acids Res..

[5]  J. A. Hendricks,et al.  Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia , 2018, Nature Communications.

[6]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[7]  Sean P. Brown,et al.  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. , 2018, Cancer discovery.

[8]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[9]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[10]  B. Tuch,et al.  Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies , 2018, The Journal of clinical investigation.

[11]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[12]  E. Pomari,et al.  Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia , 2017, Molecular Cancer Therapeutics.

[13]  Marina Konopleva,et al.  Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. , 2017, Cancer cell.

[14]  J. Gribben,et al.  Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. , 2017, Journal of oncology practice.

[15]  M. Fischer,et al.  Census and evaluation of p53 target genes , 2017, Oncogene.

[16]  T. Kipps,et al.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. , 2017, The Lancet. Oncology.

[17]  T. Schulz,et al.  Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[19]  Julio Saez-Rodriguez,et al.  A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia , 2016, Cell reports.

[20]  E. Hsi,et al.  Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells , 2016, Oncotarget.

[21]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[22]  K. Wood,et al.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia , 2016, Scientific Reports.

[23]  R. Bosotti,et al.  Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications , 2016, Molecular Cancer Therapeutics.

[24]  L. Lam,et al.  Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) , 2016, Blood Cancer Journal.

[25]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[26]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[27]  A. D’Alessandro,et al.  Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry , 2015, Amino Acids.

[28]  C. Tognon,et al.  Detecting and targetting oncogenic fusion proteins in the genomic era , 2015, Biology of the cell.

[29]  J. Engelman,et al.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. , 2015, Cancer discovery.

[30]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[31]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[32]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[33]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[34]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[35]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[36]  Y. Tsunematsu,et al.  Roles of AML1/RUNX1 in T‐cell malignancy induced by loss of p53 , 2013, Cancer science.

[37]  Philippe Juin,et al.  Decoding and unlocking the BCL-2 dependency of cancer cells , 2013, Nature Reviews Cancer.

[38]  Sandro Santagata,et al.  Chaperones as thermodynamic sensors of drug–target interactions reveal kinase inhibitor specificities in living cells , 2013, Nature Biotechnology.

[39]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[40]  F. Palmieri.  The mitochondrial transporter family SLC25: identification, properties and physiopathology. , 2013, Molecular aspects of medicine.

[41]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[42]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[43]  Hana Jin,et al.  TMEM14A inhibits N-(4-hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. , 2011, Cancer letters.

[44]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[45]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[46]  D. Green,et al.  Apoptosis and oncogenesis: give and take in the BCL-2 family. , 2011, Current opinion in genetics & development.

[47]  D. Green,et al.  Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.

[48]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[49]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[50]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[51]  Yasuaki Yamada,et al.  Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells , 2009, Leukemia.

[52]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[53]  M. Heuser,et al.  High-affinity neurotrophin receptors and ligands promote leukemogenesis. , 2009, Blood.

[54]  J. Bertin,et al.  Elesclomol induces cancer cell apoptosis through oxidative stress , 2008, Molecular Cancer Therapeutics.

[55]  F. Blankenberg,et al.  In Vivo Detection of Apoptosis , 2008, Journal of Nuclear Medicine.

[56]  Rakesh Nagarajan,et al.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. , 2008, Blood.

[57]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[58]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[59]  H. Müller-Hermelink,et al.  Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. , 2007, Blood.

[60]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[61]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[62]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[63]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[64]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[65]  John J Lemasters,et al.  Role of mitochondrial permeability transition pores in mitochondrial autophagy. , 2004, The international journal of biochemistry & cell biology.

[66]  D. Ginsberg,et al.  Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis* , 2004, Journal of Biological Chemistry.

[67]  P. Sorensen,et al.  A Highly Conserved NTRK3 C-terminal Sequence in the ETV6-NTRK3 Oncoprotein Binds the Phosphotyrosine Binding Domain of Insulin Receptor Substrate-1 , 2004, Journal of Biological Chemistry.

[68]  G. Jan,et al.  Study of PTPC Composition during Apoptosis for Identification of Viral Protein Target , 2003, Annals of the New York Academy of Sciences.

[69]  O. García-Suárez,et al.  Neurotrophins and the immune system , 2003, Journal of anatomy.

[70]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[71]  P. Sorensen,et al.  The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. , 2001, Cancer research.

[72]  M. Caligiuri,et al.  Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia , 2022 .

[73]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[74]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[75]  R. von Harsdorf,et al.  p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c‐independent apoptosis blocked by Bcl‐2 , 1999, The EMBO journal.

[76]  Yusuke Nakamura,et al.  Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with Bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability , 1999, Oncogene.

[77]  P. Brousset,et al.  In vivo patterns of Bcl‐2 family protein expression in breast carcinomas in relation to apoptosis , 1999, The Journal of pathology.

[78]  K. Tanaka,et al.  Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). , 1999, Blood.

[79]  P Dubus,et al.  Expression of neurotrophins and their receptors in human bone marrow. , 1999, The American journal of pathology.

[80]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[81]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[82]  H. Findley,et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. , 1997, Blood.

[83]  U. Jaeger,et al.  Expression of the nerve growth factor receptor c‐TRK in human myeloid leukaemia cells , 1996, British journal of haematology.

[84]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Chevalier,et al.  Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. , 1994, Blood.

[86]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.